Skin Neoplasms: Clinical Trials

1722 completed, 536 terminated, 461 recruiting, 359 unknown. 1428 Phase 2, 1287 Phase 1, 477 Not applicable, 197 Phase 3, 70 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	1428	Completed 645, Terminated 274, Recruiting 162, Unknown 127, Active not recruiting 111, Withdrawn 65, Not yet recruiting 34, Suspended 8, Enrolling by invitation 2
Phase 1	1287	Completed 611, Terminated 251, Recruiting 146, Active not recruiting 101, Unknown 98, Withdrawn 51, Not yet recruiting 16, Suspended 11, Enrolling by invitation 2
Not applicable	477	Completed 246, Recruiting 86, Unknown 60, Terminated 26, Active not recruiting 22, Not yet recruiting 18, Withdrawn 15, Suspended 3, Enrolling by invitation 1
Phase 3	197	Completed 90, Active not recruiting 30, Terminated 27, Recruiting 25, Unknown 19, Withdrawn 4, Not yet recruiting 2
Early Phase 1	70	Completed 28, Terminated 13, Recruiting 12, Active not recruiting 5, Unknown 5, Not yet recruiting 4, Withdrawn 3
Phase 4	39	Completed 13, Recruiting 6, Unknown 6, Not yet recruiting 5, Terminated 5, Withdrawn 2, Active not recruiting 1, Enrolling by invitation 1

Follow this condition Literature Review of Skin Neoplasms trials Research Report on Skin Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Combination Immunotherapy Targeting Melanoma Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	30	2027-06-30	2026-08-27
Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma Temozolomide (TMZ) - Cutaneous Melanoma	Phase 2	Not yet recruiting	Assistance Publique Hopitaux De Marseille	28	2027-06-01	2026-09-08
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8	Phase 2	Recruiting	Children's Oncology Group	51	2027-05-15	2026-09-24
Suzetrigine Versus Standard Analgesia After Skin Cancer Surgery Suzetrigine, Acetaminophen Plus Ibuprofen - Postoperative Pain, Acute Pain	Phase 4	Not yet recruiting	University of Minnesota	230	2027-04-01	2026-09-25
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy - Malignant Melanoma With Metastasis, Malignant Melanoma	Phase 2	Not yet recruiting	Rapa Therapeutics LLC	65	2027-03-01	2026-03-19
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2 - Uveal Melanoma, Metastatic Cutaneous Melanoma	Phase 1	Not yet recruiting	Vastra Gotaland Region	6	2027-01-31	2026-09-09
E-MOHS Trial of TENS and Vibration During Local Anesthesia Active Vibration:TENS, Sham TENS - Pain, Procedural Pain	Not applicable	Not yet recruiting	University of Minnesota	90	2027-01-01	2026-10-06
Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma	Phase 1	Not yet recruiting	Vastra Gotaland Region	18	2027-01-01	2026-09-09
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia	Phase 2	Not yet recruiting	Fred Hutchinson Cancer Center	52	2027-01-01	2026-09-14
Neoadjuvant RP2 + Nivolumab in Patients With Melanoma RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection - MelanomaCutaneous Melanoma Resectable, Melanoma	Phase 2	Not yet recruiting	Yana Najjar	34	2026-12-31	2026-10-07
Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran) - Melanoma	Not applicable	Recruiting	University of Colorado, Denver	40	2026-12-31	2026-08-07
Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma Wide Local Excision - Cutaneous Melanoma, Stage II, Cutaneous Melanoma	Not applicable	Not yet recruiting	University of Nebraska	282	2026-12-24	2026-10-09
Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy Biospecimen Collection, Internet-Based Intervention, Medical Device Usage and Evaluation - Advanced Cutaneous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8	Phase 1	Not yet recruiting	City of Hope Medical Center	8	2026-12-23	2026-06-05
Biomechanical Characterization of Skin Properties Using Impact Based-Analysis Method (IBAM) Melanoma (Skin Cancer), Skin Carcinoma		Not yet recruiting	Centre Hospitalier Universitaire Henri Mondor, Assistance Publique Hôpitaux de Paris	10	2026-12-03	2026-10-06
Exercise and Nutritional Intervention in Patients With Melanoma Receiving Immunotherapy Structured Resistance Exercise, Individualized Nutritional Support - Melanoma	Not applicable	Not yet recruiting	Institute of Oncology Ljubljana	40	2026-12-01	2026-10-07
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)	Not applicable	Not yet recruiting	Natera, Inc.	920	2026-12-01	2026-08-04
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma Fianlimab, Cemiplimab - Melanoma (Skin)	Phase 2	Not yet recruiting	University of California, Irvine	35	2026-12-01	2026-09-11
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma	Phase 3	Not yet recruiting	Scancell Ltd	550	2026-12-01	2026-09-11
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8	Phase 2	Not yet recruiting	Fred Hutchinson Cancer Center	50	2026-12-01	2026-09-17
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial Internet-Based Intervention, Interview, Questionnaire Administration - Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm	Not applicable	Not yet recruiting	University of Michigan Rogel Cancer Center	142	2026-12-01	2026-10-15

Showing 20 of 3622. Sign in to see all of them.

Narrower conditions

Melanoma (3197)  ·  Carcinoma, Non-Small-Cell Lung (413)  ·  Neoplasms (332)  ·  Breast Neoplasms (314)  ·  Carcinoma, Renal Cell (296)  ·  Neoplasm Metastasis (285)  ·  Colorectal Neoplasms (234)  ·  Lung Neoplasms (231)  ·  Ovarian Neoplasms (197)  ·  Squamous Cell Carcinoma of Head and Neck (181)  ·  Sarcoma (177)  ·  Pancreatic Neoplasms (170)  ·  Head and Neck Neoplasms (167)  ·  Stomach Neoplasms (141)

Broader conditions

Skin and Connective Tissue Diseases (3622)  ·  Neoplasms by Site (3607)  ·  Skin Diseases (3598)  ·  Neoplasms by Histologic Type (3385)  ·  Neoplasms (3290)  ·  Neoplasms, Nerve Tissue (3224)  ·  Neuroectodermal Tumors (3223)  ·  Neoplasms, Germ Cell and Embryonal (3213)  ·  Nevi and Melanomas (3208)  ·  Neuroendocrine Tumors (3207)  ·  Neoplasms, Glandular and Epithelial (735)  ·  Carcinoma (637)  ·  Urogenital Diseases (618)  ·  Respiratory Tract Diseases (598)

Interventions

pembrolizumab (315)  ·  Nivolumab (286)  ·  Ipilimumab (256)  ·  Cyclophosphamide (147)  ·  aldesleukin (139)  ·  Interleukin-2 (108)  ·  trametinib (82)  ·  Dacarbazine (77)  ·  Temozolomide (77)  ·  dabrafenib (77)  ·  fludarabine (75)  ·  Vemurafenib (71)  ·  fludarabine phosphate (70)  ·  Biopsy (59)  ·  binimetinib (47)

Sponsors

National Cancer Institute (NCI) (217)  ·  M.D. Anderson Cancer Center (112)  ·  Bristol-Myers Squibb (91)  ·  Memorial Sloan Kettering Cancer Center (67)  ·  Mayo Clinic (49)  ·  Novartis Pharmaceuticals (46)  ·  Hoffmann-La Roche (45)  ·  H. Lee Moffitt Cancer Center and Research Institute (44)  ·  Pfizer (38)  ·  Merck Sharp & Dohme LLC (36)  ·  Dana-Farber Cancer Institute (28)  ·  GlaxoSmithKline (27)  ·  Peking University Cancer Hospital & Institute (25)  ·  Fred Hutchinson Cancer Center (24)  ·  Massachusetts General Hospital (24)

Countries

United States (2222)  ·  France (371)  ·  Australia (291)  ·  Germany (289)  ·  United Kingdom (282)  ·  Spain (279)  ·  Italy (273)  ·  Canada (243)  ·  Netherlands (176)  ·  Belgium (166)  ·  China (164)  ·  Switzerland (154)  ·  Israel (115)  ·  Poland (112)  ·  Sweden (100)

Top investigators

Steven A Rosenberg, M.D. (29)  ·  Steven A. Rosenberg, MD, PhD (27)  ·  F. Stephen Hodi, MD (12)  ·  Paul Chapman, MD (10)  ·  Craig L Slingluff, MD (9)  ·  Craig L. Slingluff, MD (9)

Results publications

PMID 36648215, PMID 25667295, PMID 24983357, PMID 39504507, PMID 22555974, PMID 22256804, PMID 25649350, PMID 26446943, PMID 31395089, PMID 32746839, PMID 23457002, PMID 23861247, PMID 24408395, PMID 24577748, PMID 27864013, PMID 30202085, PMID 30736858, PMID 31401903, PMID 32305010, PMID 32747469, PMID 33360855, PMID 33795208, PMID 34225229, PMID 34754076, PMID 36653848, PMID 39462179, PMID 40721981, PMID 41811823, PMID 20856802, PMID 21600759, PMID 21639810, PMID 23054107, PMID 23295794, PMID 23504141, PMID 24145345, PMID 24418949, PMID 24695685, PMID 25432172, PMID 25837513, PMID 26902923, PMID 28592387, PMID 28662232, PMID 29896663, PMID 31166680, PMID 31406564, PMID 31864178, PMID 32303612, PMID 32350119, PMID 32596742, PMID 33089943

NIH funding

2023 (40), 2019 (26), 2016 (24), 2018 (23), 2014 (16), 2015 (16), P30CA015083 (15), P30CA072720 (13), 2025 (12), 2009 (11), P30CA015704 (11), P30CA043703 (11), U10CA032102 (11), U10CA180820 (11), P30CA016672 (10)